Clinical Cancer Research AACR Conference on Cancer Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schewe, D. M.
Right arrow Articles by Allgayer, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schewe, D. M.
Right arrow Articles by Allgayer, H.
Clinical Cancer Research Vol. 9, 2267-2276, June 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Tumor-specific Transcription Factor Binding to an Activator Protein-2/Sp1 Element of the Urokinase-type Plasminogen Activator Receptor Promoter in a First Large Series of Resected Gastrointestinal Cancers1

Denis Martin Schewe, Joerg H. Leupold, Douglas D. Boyd, Ernst R. Lengyel, Heng Wang, Klaus Uwe Gruetzner, Friedrich W. Schildberg, Karl W. Jauch and Heike Allgayer2

Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University of Munich, 81377 Munich, Germany [D. M. S., J. H. L., K. U. G., F. W. S., K. W. J., H. A.]; Department of Cancer Biology, M. D. Anderson Cancer Center, Houston, Texas 77030 [D. D. B., H. W.]; and Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Comprehensive Cancer Center and CancerResearch Institute, San Francisco, California [E. R. L.]

Purpose: Evidence for transactivation of genes via specific promoter elements has been derived from studies on tumor cell lines but rarely on resected tumors. However, the proof of an in vivo relevance and the identification of patients with a potential tumor-specific gene expression is essential to transfer molecular-targeting strategies into clinical applications. This study gives the first clinical evidence that urokinase-type plasminogen activator receptor (u-PAR) gene expression is tumor-specifically regulated via an activator protein (AP)-2/Sp1 promoter element in a large patient subpopulation.

Experimental Design: In 145 gastrointestinal cancer patients, electrophoretic mobility shift analysis and supershift assays for u-PAR-promoter region -152/-135 were performed in tumors and corresponding normal tissues. u-PAR protein levels were measured by ELISA.

Results: Binding of Sp1 to region -152/-135 in tumors in contrast to corresponding normal mucosae was observed in 55% of colorectal and in 52% of gastric cancer patients. Tumor-specific binding of an AP-2-related factor was seen in 59% of colorectal and in 63% of gastric cancer patients. A significant correlation between AP-2 (P < 0.0001) and Sp1 (P = 0.0003) binding with a high u-PAR expression was observed in tumors but not in normal mucosae. Tissues of five nontumor patients did not show transcription factor binding to this region.

Conclusions: This is the first study to show the tumor-specific binding of trans-activators to the u-PAR promoter region (-152/-135) biochemically in a large series of resected tumors. For the subpopulation of ~60% of patients with tumor-restricted u-PAR-transactivation, a molecular targeting of this region or its activating pathways should be pursued as a new antimetastasis therapy approach.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
G. D. Maurer, J. H. Leupold, D. M. Schewe, T. Biller, R. E. Kates, H.-M. Hornung, U. Lau-Werner, S. Post, and H. Allgayer
Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1123 - 1132.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. M. Schewe, T. Biller, G. Maurer, I. A. Asangani, J. H. Leupold, E. R. Lengyel, S. Post, and H. Allgayer
Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2{alpha}-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers
Clin. Cancer Res., December 15, 2005; 11(24): 8538 - 8548.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Wang, L. Yang, Md. S. Jamaluddin, and D. D. Boyd
The Kruppel-like KLF4 Transcription Factor, a Novel Regulator of Urokinase Receptor Expression, Drives Synthesis of This Binding Site in Colonic Crypt Luminal Surface Epithelial Cells
J. Biol. Chem., May 21, 2004; 279(21): 22674 - 22683.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Trisciuoglio, A. Iervolino, A. Candiloro, G. Fibbi, M. Fanciulli, U. Zangemeister-Wittke, G. Zupi, and D. Del Bufalo
bcl-2 Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation: INVOLVEMENT OF ERK1/ERK2 ACTIVITY
J. Biol. Chem., February 20, 2004; 279(8): 6737 - 6745.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.